News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|April 18, 2010

PTV2 Title Panic Attacks

Panic Attacks

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

anxiety

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

May 20th 2026

lifestyle medicine

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

ByFarah Abbas, BS,Asim A. Shah, MD

April 29th 2026

breasts

Prolactin Monitoring for Antipsychotics and the Impact of Stress

ByNilamadhab Kar, MD, DPM, DNB, FRCPsych

April 22nd 2026

EMP-01 for Social Anxiety Disorder Demonstrates Meaningful Improvements in Phase 2a Study

April 22nd 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Suicide Risk Assessment in Patients Denying Suicidal Intent

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research